APO Research
Talk to an analyst

APO RESEARCH · REPORT

Oligonucleotide Therapeutics

Many pharmaceutical companies were conducting research on oligonucleotide therapy, which employs chemically synthesized nucleotide-like small molecule drugs with potential specificity similar to that of therapeutic antibodies.

Explore the product
View pricing & licenses

Product & engineering

Understand the product.

Many pharmaceutical companies were conducting research on oligonucleotide therapy, which employs chemically synthesized nucleotide-like small molecule drugs with potential specificity similar to that of therapeutic antibodies.

Although several types of oligonucleotide therapies exist, five of them are compared here, including the ones targeting nucleic acids (such as mRNA) or proteins, as well as others intended for stimulation of the immune system. DDS is generally used with oligonucleotide therapy, as it is difficult for these molecules to penetrate cell membrane when administered on their own.

Selected research

Market Analysis & Forecast

Global Oligonucleotide Therapeutics Market Analysis and Forecast 2026-2032

31 December 2025196 pages

Choose your research edition.

Industry ResearchOligonucleotide Therapeutics Industry Research Report 2026111 pages · $2,950 USDIndustry Growth & TrendsGlobal Oligonucleotide Therapeutics Industry Growth and Trends Forecast to 203289 pages · $3,450 USDMarket StructureGlobal Oligonucleotide Therapeutics Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032182 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Oligonucleotide Therapeutics Market Outlook and Growth Opportunities 2026195 pages · $4,250 USDMarket Analysis & ForecastGlobal Oligonucleotide Therapeutics Market Analysis and Forecast 2026-2032196 pages · $4,950 USD

Market perspective

Many pharmaceutical companies were conducting research on oligonucleotide therapy, which employs chemically synthesized nucleotide-like small molecule drugs with potential specificity similar to that of therapeutic antibodies.

Although several types of oligonucleotide therapies exist, five of them are compared here, including the ones targeting nucleic acids (such as mRNA) or proteins, as well as others intended for stimulation of the immune system. DDS is generally used with oligonucleotide therapy, as it is difficult for these molecules to penetrate cell membrane when administered on their own.

Biogen is the industry's biggest player, with more than 76 percent of 2018 revenue, followed by Sarepta Therapeutics and Jazz Pharmaceuticals, with 13.35 percent and 6.63 percent, respectively. North America and Europe are the most important regions, accounting for more than 80 percent of the combined income.

Read the full market overview

Report Includes

This report presents an overview of global market for Oligonucleotide Therapeutics, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Oligonucleotide Therapeutics, also provides the revenue of main regions and countries. Of the upcoming market potential for Oligonucleotide Therapeutics, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Oligonucleotide Therapeutics revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Oligonucleotide Therapeutics market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Oligonucleotide Therapeutics revenue, projected growth trends, production technology, application and end-user industry.

Oligonucleotide Therapeutics Segment by Company

Biogen

Sarepta Therapeutics

Jazz Pharmaceuticals

Bausch & Lomb

Alnylam Pharmaceuticals

Dynavax Technologies

Kastle therapeutics

Akcea Therapeutics

Oligonucleotide Therapeutics Segment by Type

Antisense Oligonucleotide

Aptamer

Other

Oligonucleotide Therapeutics Segment by Application

Neuromuscular Diseases

ATTR

Hepatic VOD

Other

Oligonucleotide Therapeutics Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Oligonucleotide Therapeutics market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Oligonucleotide Therapeutics and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Oligonucleotide Therapeutics.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Oligonucleotide Therapeutics in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Oligonucleotide Therapeutics company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Oligonucleotide Therapeutics revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Oligonucleotide Therapeutics Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Antisense Oligonucleotide Major Player Table 3. Aptamer Major Player Table 4. Other Major Player Table 5. Global Oligonucleotide Therapeutics Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 6. Neuromuscular Diseases Major Player Table 7. ATTR Major Player Table 8. Hepatic VOD Major Player Table 9. Other Major Player Table 10. Oligonucleotide Therapeutics Industry Trends Table 11. Oligonucleotide Therapeutics Industry Drivers Table 12. Oligonucleotide Therapeutics Industry Opportunities and Challenges Table 13. Oligonucleotide Therapeutics Industry Restraints Table 14. Global Oligonucleotide Therapeutics Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 15. Global Oligonucleotide Therapeutics Market Size by Region (2021-2026) & (US$ Million) Table 16. Global Oligonucleotide Therapeutics Market Share by Region (2021-2026) Table 17. Global Oligonucleotide Therapeutics Market Size by Region (2027-2032) & (US$ Million) Table 18. Global Oligonucleotide Therapeutics Market Share by Region (2027-2032) Table 19. Global Oligonucleotide Therapeutics Revenue by Players (US$ Million) & (2021-2026) Table 20. Global Oligonucleotide Therapeutics Revenue Market Share by Players (2021-2026) Table 21. Global Oligonucleotide Therapeutics Key Players Ranking, 2024 VS 2025 VS 2026 Table 22. Global Oligonucleotide Therapeutics Key Players Headquarters & Area Served Table 23. Global Oligonucleotide Therapeutics Players, Product Type & Application Table 24. Global Oligonucleotide Therapeutics Players Establishment Date Table 25. Global Players Market Concentration Ratio (CR5 and HHI) Table 26. Global Oligonucleotide Therapeutics by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 27. Global Oligonucleotide Therapeutics Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 28. Global Oligonucleotide Therapeutics Revenue by Type (2021-2026) & (US$ Million) Table 29. Global Oligonucleotide Therapeutics Revenue by Type (2027-2032) & (US$ Million) Table 30. Global Oligonucleotide Therapeutics Revenue Market Share by Type (2021-2026) Table 31. Global Oligonucleotide Therapeutics Revenue Market Share by Type (2027-2032) Table 32. Global Oligonucleotide Therapeutics Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 33. Global Oligonucleotide Therapeutics Revenue by Application (2021-2026) & (US$ Million) Table 34. Global Oligonucleotide Therapeutics Revenue by Application (2027-2032) & (US$ Million) Table 35. Global Oligonucleotide Therapeutics Revenue Market Share by Application (2021-2026) Table 36. Global Oligonucleotide Therapeutics Revenue Market Share by Application (2027-2032) Table 37. Biogen Company Information Table 38. Biogen Business Overview Table 39. Biogen Oligonucleotide Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026) Table 40. Biogen Oligonucleotide Therapeutics Product Portfolio Table 41. Biogen Recent Development Table 42. Sarepta Therapeutics Company Information Table 43. Sarepta Therapeutics Business Overview Table 44. Sarepta Therapeutics Oligonucleotide Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026) Table 45. Sarepta Therapeutics Oligonucleotide Therapeutics Product Portfolio Table 46. Sarepta Therapeutics Recent Development Table 47. Jazz Pharmaceuticals Company Information Table 48. Jazz Pharmaceuticals Business Overview Table 49. Jazz Pharmaceuticals Oligonucleotide Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026) Table 50. Jazz Pharmaceuticals Oligonucleotide Therapeutics Product Portfolio Table 51. Jazz Pharmaceuticals Recent Development Table 52. Bausch & Lomb Company Information Table 53. Bausch & Lomb Business Overview Table 54. Bausch & Lomb Oligonucleotide Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026) Table 55. Bausch & Lomb Oligonucleotide Therapeutics Product Portfolio Table 56. Bausch & Lomb Recent Development Table 57. Alnylam Pharmaceuticals Company Information Table 58. Alnylam Pharmaceuticals Business Overview Table 59. Alnylam Pharmaceuticals Oligonucleotide Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026) Table 60. Alnylam Pharmaceuticals Oligonucleotide Therapeutics Product Portfolio Table 61. Alnylam Pharmaceuticals Recent Development Table 62. Dynavax Technologies Company Information Table 63. Dynavax Technologies Business Overview Table 64. Dynavax Technologies Oligonucleotide Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026) Table 65. Dynavax Technologies Oligonucleotide Therapeutics Product Portfolio Table 66. Dynavax Technologies Recent Development Table 67. Kastle therapeutics Company Information Table 68. Kastle therapeutics Business Overview Table 69. Kastle therapeutics Oligonucleotide Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026) Table 70. Kastle therapeutics Oligonucleotide Therapeutics Product Portfolio Table 71. Kastle therapeutics Recent Development Table 72. Akcea Therapeutics Company Information Table 73. Akcea Therapeutics Business Overview Table 74. Akcea Therapeutics Oligonucleotide Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026) Table 75. Akcea Therapeutics Oligonucleotide Therapeutics Product Portfolio Table 76. Akcea Therapeutics Recent Development Table 77. North America Oligonucleotide Therapeutics Revenue by Type (2021-2026) & (US$ Million) Table 78. North America Oligonucleotide Therapeutics Revenue by Type (2027-2032) & (US$ Million) Table 79. North America Oligonucleotide Therapeutics Revenue by Application (2021-2026) & (US$ Million) Table 80. North America Oligonucleotide Therapeutics Revenue by Application (2027-2032) & (US$ Million) Table 81. North America Oligonucleotide Therapeutics Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 82. North America Oligonucleotide Therapeutics Revenue by Country (2021-2026) & (US$ Million) Table 83. North America Oligonucleotide Therapeutics Revenue by Country (US$ Million) & (2027-2032) Table 84. Europe Oligonucleotide Therapeutics Revenue by Type (2021-2026) & (US$ Million) Table 85. Europe Oligonucleotide Therapeutics Revenue by Type (2027-2032) & (US$ Million) Table 86. Europe Oligonucleotide Therapeutics Revenue by Application (2021-2026) & (US$ Million) Table 87. Europe Oligonucleotide Therapeutics Revenue by Application (2027-2032) & (US$ Million) Table 88. Europe Oligonucleotide Therapeutics Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 89. Europe Oligonucleotide Therapeutics Revenue by Country (2021-2026) & (US$ Million) Table 90. Europe Oligonucleotide Therapeutics Revenue by Country (US$ Million) & (2027-2032) Table 91. China Oligonucleotide Therapeutics Revenue by Type (2021-2026) & (US$ Million) Table 92. China Oligonucleotide Therapeutics Revenue by Type (2027-2032) & (US$ Million) Table 93. China Oligonucleotide Therapeutics Revenue by Application (2021-2026) & (US$ Million) Table 94. China Oligonucleotide Therapeutics Revenue by Application (2027-2032) & (US$ Million) Table 95. Asia Oligonucleotide Therapeutics Revenue by Type (2021-2026) & (US$ Million) Table 96. Asia Oligonucleotide Therapeutics Revenue by Type (2027-2032) & (US$ Million) Table 97. Asia Oligonucleotide Therapeutics Revenue by Application (2021-2026) & (US$ Million) Table 98. Asia Oligonucleotide Therapeutics Revenue by Application (2027-2032) & (US$ Million) Table 99. Asia Oligonucleotide Therapeutics Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 100. Asia Oligonucleotide Therapeutics Revenue by Region (US$ Million) & (2021-2026) Table 101. Asia Oligonucleotide Therapeutics Revenue by Region (US$ Million) & (2027-2032) Table 102. SAMEA Oligonucleotide Therapeutics Revenue by Type (2021-2026) & (US$ Million) Table 103. SAMEA Oligonucleotide Therapeutics Revenue by Type (2027-2032) & (US$ Million) Table 104. SAMEA Oligonucleotide Therapeutics Revenue by Application (2021-2026) & (US$ Million) Table 105. SAMEA Oligonucleotide Therapeutics Revenue by Application (2027-2032) & (US$ Million) Table 106. SAMEA Oligonucleotide Therapeutics Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 107. SAMEA Oligonucleotide Therapeutics Revenue by Country (2021-2026) & (US$ Million) Table 108. SAMEA Oligonucleotide Therapeutics Revenue by Country (US$ Million) & (2027-2032) Table 109. Research Programs/Design for This Report Table 110. Authors List of This Report Table 111. Secondary Sources Table 112. Primary Sources List of Figures Figure 1. Oligonucleotide Therapeutics Image Figure 2. Global Oligonucleotide Therapeutics Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Oligonucleotide Therapeutics Market Size Share 2021 VS 2025 VS 2032 Figure 4. Antisense Oligonucleotide Image Figure 5. Aptamer Image Figure 6. Other Image Figure 7. Global Oligonucleotide Therapeutics Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 8. Global Oligonucleotide Therapeutics Market Size Share 2021 VS 2025 VS 2032 Figure 9. Neuromuscular Diseases Image Figure 10. ATTR Image Figure 11. Hepatic VOD Image Figure 12. Other Image Figure 13. Global Oligonucleotide Therapeutics Market Size (US$ Million) & (2021-2032) Figure 14. Global Oligonucleotide Therapeutics Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 15. Global Oligonucleotide Therapeutics Market Share by Region: 2021 VS 2025 VS 2032 Figure 16. Global Oligonucleotide Therapeutics Players Revenue Share Top 10 and Top 5 in 2025 Figure 17. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 18. Global Oligonucleotide Therapeutics Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 19. Global Oligonucleotide Therapeutics Revenue Market Share 2021 VS 2025 VS 2032 Figure 20. Global Oligonucleotide Therapeutics Revenue Market Share by Type (2021-2032) Figure 21. Global Oligonucleotide Therapeutics Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 22. Global Oligonucleotide Therapeutics Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 23. Global Oligonucleotide Therapeutics Revenue Market Share by Application (2021-2032) Figure 24. North America Oligonucleotide Therapeutics Revenue YoY Growth (2021-2032) & (US$ Million) Figure 25. North America Oligonucleotide Therapeutics Revenue Share by Type (2021-2032) Figure 26. North America Oligonucleotide Therapeutics Revenue Share by Application (2021-2032) Figure 27. North America Oligonucleotide Therapeutics Revenue Share by Country (2021-2032) Figure 28. United States Oligonucleotide Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 29. Canada Oligonucleotide Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 30. Mexico Oligonucleotide Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 31. Europe Oligonucleotide Therapeutics Revenue YoY Growth (2021-2032) & (US$ Million) Figure 32. Europe Oligonucleotide Therapeutics Revenue Share by Type (2021-2032) Figure 33. Europe Oligonucleotide Therapeutics Revenue Share by Application (2021-2032) Figure 34. Europe Oligonucleotide Therapeutics Revenue Share by Country (2021-2032) Figure 35. Germany Oligonucleotide Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 36. France Oligonucleotide Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 37. U.K. Oligonucleotide Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. Italy Oligonucleotide Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. Spain Oligonucleotide Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. Russia Oligonucleotide Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. Netherlands Oligonucleotide Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 42. Nordic Countries Oligonucleotide Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 43. China Oligonucleotide Therapeutics Revenue YoY Growth (2021-2032) & (US$ Million) Figure 44. China Oligonucleotide Therapeutics Revenue Share by Type (2021-2032) Figure 45. China Oligonucleotide Therapeutics Revenue Share by Application (2021-2032) Figure 46. Asia Oligonucleotide Therapeutics Revenue YoY Growth (2021-2032) & (US$ Million) Figure 47. Asia Oligonucleotide Therapeutics Revenue Share by Type (2021-2032) Figure 48. Asia Oligonucleotide Therapeutics Revenue Share by Application (2021-2032) Figure 49. Asia Oligonucleotide Therapeutics Revenue Share by Region (2021-2032) Figure 50. Japan Oligonucleotide Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 51. South Korea Oligonucleotide Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 52. India Oligonucleotide Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. Australia Oligonucleotide Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. Taiwan Oligonucleotide Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 55. Southeast Asia Oligonucleotide Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 56. SAMEA Oligonucleotide Therapeutics Revenue YoY Growth (2021-2032) & (US$ Million) Figure 57. SAMEA Oligonucleotide Therapeutics Revenue Share by Type (2021-2032) Figure 58. SAMEA Oligonucleotide Therapeutics Revenue Share by Application (2021-2032) Figure 59. SAMEA Oligonucleotide Therapeutics Revenue Share by Country (2021-2032) Figure 60. Brazil Oligonucleotide Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 61. Argentina Oligonucleotide Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 62. Chile Oligonucleotide Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Colombia Oligonucleotide Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Peru Oligonucleotide Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. Saudi Arabia Oligonucleotide Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. Israel Oligonucleotide Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. UAE Oligonucleotide Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. Turkey Oligonucleotide Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. Iran Oligonucleotide Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 70. Egypt Oligonucleotide Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 71. Years Considered Figure 72. Research Process Figure 73. Key Executives Interviewed

Scope & coverage.

Types
  • Antisense Oligonucleotide
  • Aptamer
  • Other
Applications
  • Neuromuscular Diseases
  • ATTR
  • Hepatic VOD
  • Other
Companies covered
  • Biogen
  • Sarepta Therapeutics
  • Jazz Pharmaceuticals
  • Bausch & Lomb
  • Alnylam Pharmaceuticals
  • Dynavax Technologies
  • Kastle therapeutics
  • Akcea Therapeutics

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Oligonucleotide Therapeutics Market by Type
  3. 1.2.1 Global Oligonucleotide Therapeutics Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Antisense Oligonucleotide
  5. 1.2.3 Aptamer
  6. 1.2.4 Other
  7. 1.3 Oligonucleotide Therapeutics Market by Application
  8. 1.3.1 Global Oligonucleotide Therapeutics Market Size by Application, 2021 VS 2025 VS 2032
  9. 1.3.2 Neuromuscular Diseases
  10. 1.3.3 ATTR
  11. 1.3.4 Hepatic VOD
  12. 1.3.5 Other
  13. 1.4 Assumptions and Limitations
  14. 1.5 Study Goals and Objectives
2 Oligonucleotide Therapeutics Market Dynamics
  1. 2.1 Oligonucleotide Therapeutics Industry Trends
  2. 2.2 Oligonucleotide Therapeutics Industry Drivers
  3. 2.3 Oligonucleotide Therapeutics Industry Opportunities and Challenges
  4. 2.4 Oligonucleotide Therapeutics Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Oligonucleotide Therapeutics Market Perspective (2021-2032)
  2. 3.2 Global Oligonucleotide Therapeutics Growth Trends by Region
  3. 3.2.1 Global Oligonucleotide Therapeutics Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Oligonucleotide Therapeutics Market Size by Region (2021-2026)
  5. 3.2.3 Global Oligonucleotide Therapeutics Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Oligonucleotide Therapeutics Revenue by Players
  2. 4.1.1 Global Oligonucleotide Therapeutics Revenue by Players (2021-2026)
  3. 4.1.2 Global Oligonucleotide Therapeutics Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Oligonucleotide Therapeutics Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Oligonucleotide Therapeutics Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Oligonucleotide Therapeutics Key Players Headquarters & Area Served
  7. 4.4 Global Oligonucleotide Therapeutics Players, Product Type & Application
  8. 4.5 Global Oligonucleotide Therapeutics Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Oligonucleotide Therapeutics Market CR5 and HHI
  11. 4.6.3 2025 Oligonucleotide Therapeutics Tier 1, Tier 2, and Tier 3
5 Oligonucleotide Therapeutics Market Size by Type
  1. 5.1 Global Oligonucleotide Therapeutics Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Oligonucleotide Therapeutics Revenue by Type (2021-2032)
  3. 5.3 Global Oligonucleotide Therapeutics Revenue Market Share by Type (2021-2032)
6 Oligonucleotide Therapeutics Market Size by Application
  1. 6.1 Global Oligonucleotide Therapeutics Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Oligonucleotide Therapeutics Revenue by Application (2021-2032)
  3. 6.3 Global Oligonucleotide Therapeutics Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 Biogen
  2. 7.1.1 Biogen Company Information
  3. 7.1.2 Biogen Business Overview
  4. 7.1.3 Biogen Oligonucleotide Therapeutics Revenue and Gross Margin (2021-2026)
  5. 7.1.4 Biogen Oligonucleotide Therapeutics Product Portfolio
  6. 7.1.5 Biogen Recent Developments
  7. 7.2 Sarepta Therapeutics
  8. 7.2.1 Sarepta Therapeutics Company Information
  9. 7.2.2 Sarepta Therapeutics Business Overview
  10. 7.2.3 Sarepta Therapeutics Oligonucleotide Therapeutics Revenue and Gross Margin (2021-2026)
  11. 7.2.4 Sarepta Therapeutics Oligonucleotide Therapeutics Product Portfolio
  12. 7.2.5 Sarepta Therapeutics Recent Developments
  13. 7.3 Jazz Pharmaceuticals
  14. 7.3.1 Jazz Pharmaceuticals Company Information
  15. 7.3.2 Jazz Pharmaceuticals Business Overview
  16. 7.3.3 Jazz Pharmaceuticals Oligonucleotide Therapeutics Revenue and Gross Margin (2021-2026)
  17. 7.3.4 Jazz Pharmaceuticals Oligonucleotide Therapeutics Product Portfolio
  18. 7.3.5 Jazz Pharmaceuticals Recent Developments
  19. 7.4 Bausch & Lomb
  20. 7.4.1 Bausch & Lomb Company Information
  21. 7.4.2 Bausch & Lomb Business Overview
  22. 7.4.3 Bausch & Lomb Oligonucleotide Therapeutics Revenue and Gross Margin (2021-2026)
  23. 7.4.4 Bausch & Lomb Oligonucleotide Therapeutics Product Portfolio
  24. 7.4.5 Bausch & Lomb Recent Developments
  25. 7.5 Alnylam Pharmaceuticals
  26. 7.5.1 Alnylam Pharmaceuticals Company Information
  27. 7.5.2 Alnylam Pharmaceuticals Business Overview
  28. 7.5.3 Alnylam Pharmaceuticals Oligonucleotide Therapeutics Revenue and Gross Margin (2021-2026)
  29. 7.5.4 Alnylam Pharmaceuticals Oligonucleotide Therapeutics Product Portfolio
  30. 7.5.5 Alnylam Pharmaceuticals Recent Developments
  31. 7.6 Dynavax Technologies
  32. 7.6.1 Dynavax Technologies Company Information
  33. 7.6.2 Dynavax Technologies Business Overview
  34. 7.6.3 Dynavax Technologies Oligonucleotide Therapeutics Revenue and Gross Margin (2021-2026)
  35. 7.6.4 Dynavax Technologies Oligonucleotide Therapeutics Product Portfolio
  36. 7.6.5 Dynavax Technologies Recent Developments
  37. 7.7 Kastle therapeutics
  38. 7.7.1 Kastle therapeutics Company Information
  39. 7.7.2 Kastle therapeutics Business Overview
  40. 7.7.3 Kastle therapeutics Oligonucleotide Therapeutics Revenue and Gross Margin (2021-2026)
  41. 7.7.4 Kastle therapeutics Oligonucleotide Therapeutics Product Portfolio
  42. 7.7.5 Kastle therapeutics Recent Developments
  43. 7.8 Akcea Therapeutics
  44. 7.8.1 Akcea Therapeutics Company Information
  45. 7.8.2 Akcea Therapeutics Business Overview
  46. 7.8.3 Akcea Therapeutics Oligonucleotide Therapeutics Revenue and Gross Margin (2021-2026)
  47. 7.8.4 Akcea Therapeutics Oligonucleotide Therapeutics Product Portfolio
  48. 7.8.5 Akcea Therapeutics Recent Developments
8 North America
  1. 8.1 North America Oligonucleotide Therapeutics Revenue (2021-2032)
  2. 8.2 North America Oligonucleotide Therapeutics Revenue by Type (2021-2032)
  3. 8.2.1 North America Oligonucleotide Therapeutics Revenue by Type (2021-2026)
  4. 8.2.2 North America Oligonucleotide Therapeutics Revenue by Type (2027-2032)
  5. 8.3 North America Oligonucleotide Therapeutics Revenue Share by Type (2021-2032)
  6. 8.4 North America Oligonucleotide Therapeutics Revenue by Application (2021-2032)
  7. 8.4.1 North America Oligonucleotide Therapeutics Revenue by Application (2021-2026)
  8. 8.4.2 North America Oligonucleotide Therapeutics Revenue by Application (2027-2032)
  9. 8.5 North America Oligonucleotide Therapeutics Revenue Share by Application (2021-2032)
  10. 8.6 North America Oligonucleotide Therapeutics Revenue by Country
  11. 8.6.1 North America Oligonucleotide Therapeutics Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Oligonucleotide Therapeutics Revenue by Country (2021-2026)
  13. 8.6.3 North America Oligonucleotide Therapeutics Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
  16. 8.6.6 Mexico
9 Europe
  1. 9.1 Europe Oligonucleotide Therapeutics Revenue (2021-2032)
  2. 9.2 Europe Oligonucleotide Therapeutics Revenue by Type (2021-2032)
  3. 9.2.1 Europe Oligonucleotide Therapeutics Revenue by Type (2021-2026)
  4. 9.2.2 Europe Oligonucleotide Therapeutics Revenue by Type (2027-2032)
  5. 9.3 Europe Oligonucleotide Therapeutics Revenue Share by Type (2021-2032)
  6. 9.4 Europe Oligonucleotide Therapeutics Revenue by Application (2021-2032)
  7. 9.4.1 Europe Oligonucleotide Therapeutics Revenue by Application (2021-2026)
  8. 9.4.2 Europe Oligonucleotide Therapeutics Revenue by Application (2027-2032)
  9. 9.5 Europe Oligonucleotide Therapeutics Revenue Share by Application (2021-2032)
  10. 9.6 Europe Oligonucleotide Therapeutics Revenue by Country
  11. 9.6.1 Europe Oligonucleotide Therapeutics Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Oligonucleotide Therapeutics Revenue by Country (2021-2026)
  13. 9.6.3 Europe Oligonucleotide Therapeutics Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Russia
  19. 9.6.9 Spain
  20. 9.6.10 Netherlands
  21. 9.6.11 Switzerland
  22. 9.6.12 Sweden
  23. 9.6.13 Poland
10 China
  1. 10.1 China Oligonucleotide Therapeutics Revenue (2021-2032)
  2. 10.2 China Oligonucleotide Therapeutics Revenue by Type (2021-2032)
  3. 10.2.1 China Oligonucleotide Therapeutics Revenue by Type (2021-2026)
  4. 10.2.2 China Oligonucleotide Therapeutics Revenue by Type (2027-2032)
  5. 10.3 China Oligonucleotide Therapeutics Revenue Share by Type (2021-2032)
  6. 10.4 China Oligonucleotide Therapeutics Revenue by Application (2021-2032)
  7. 10.4.1 China Oligonucleotide Therapeutics Revenue by Application (2021-2026)
  8. 10.4.2 China Oligonucleotide Therapeutics Revenue by Application (2027-2032)
  9. 10.5 China Oligonucleotide Therapeutics Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Oligonucleotide Therapeutics Revenue (2021-2032)
  2. 11.2 Asia Oligonucleotide Therapeutics Revenue by Type (2021-2032)
  3. 11.2.1 Asia Oligonucleotide Therapeutics Revenue by Type (2021-2026)
  4. 11.2.2 Asia Oligonucleotide Therapeutics Revenue by Type (2027-2032)
  5. 11.3 Asia Oligonucleotide Therapeutics Revenue Share by Type (2021-2032)
  6. 11.4 Asia Oligonucleotide Therapeutics Revenue by Application (2021-2032)
  7. 11.4.1 Asia Oligonucleotide Therapeutics Revenue by Application (2021-2026)
  8. 11.4.2 Asia Oligonucleotide Therapeutics Revenue by Application (2027-2032)
  9. 11.5 Asia Oligonucleotide Therapeutics Revenue Share by Application (2021-2032)
  10. 11.6 Asia Oligonucleotide Therapeutics Revenue by Country
  11. 11.6.1 Asia Oligonucleotide Therapeutics Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Oligonucleotide Therapeutics Revenue by Country (2021-2026)
  13. 11.6.3 Asia Oligonucleotide Therapeutics Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Oligonucleotide Therapeutics Revenue (2021-2032)
  2. 12.2 SAMEA Oligonucleotide Therapeutics Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Oligonucleotide Therapeutics Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Oligonucleotide Therapeutics Revenue by Type (2027-2032)
  5. 12.3 SAMEA Oligonucleotide Therapeutics Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Oligonucleotide Therapeutics Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA Oligonucleotide Therapeutics Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA Oligonucleotide Therapeutics Revenue by Application (2027-2032)
  9. 12.5 SAMEA Oligonucleotide Therapeutics Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA Oligonucleotide Therapeutics Revenue by Country
  11. 12.6.1 SAMEA Oligonucleotide Therapeutics Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Oligonucleotide Therapeutics Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Oligonucleotide Therapeutics Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst